产品名称
Azelaoyl-PAF, Avanti Research™ - A Croda Brand 870601P, powder
SMILES string
[O-]P(OCC[N+](C)(C)C)(OC[C@]([H])(OC(CCCCCCCC(O)=O)=O)COCCCCCCCCCCCCCCCC)=O
InChI
1S/C33H66NO9P/c1-5-6-7-8-9-10-11-12-13-14-15-16-20-23-27-40-29-31(30-42-44(38,39)41-28-26-34(2,3)4)43-33(37)25-22-19-17-18-21-24-32(35)36/h31H,5-30H2,1-4H3,(H-,35,36,38,39)/t31-/m1/s1
InChI key
ZDFOCDTXDPKJKA-WJOKGBTCSA-N
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 1 mg (870601P-1mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 870601P
shipped in
dry ice
storage temp.
−20°C
正在寻找类似产品? 访问 产品对比指南
Application
Azelaoyl-PAF may be used to study its binding affinity with 4F or 2F anti-inflammatory peptides.
Biochem/physiol Actions
Azelaoyl-PAF (1-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine) is a low molecular weight alkyl phosphatidylcholine. It is a constituent of the lipid pool within oxidized low-density lipoprotein (oxLDL) particles. Azelaoyl-PAF serves as a high affinity ligand and agonist for peroxisome proliferator-activated receptor-γ (PPARγ).
Packaging
5 mL Clear Glass Sealed Ampule (870601P-1mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
存储类别
11 - Combustible Solids
wgk
WGK 3
Raquel F Epand et al.
Biochimica et biophysica acta, 1788(9), 1967-1975 (2009-06-30)
The peptide 4F is known to have potent anti-atherogenic activity. 4F is an 18 residue peptide that has a sequence capable of forming a class A amphipathic helix. Several other class A amphipathic helical, 18 residue peptides with the same
S S Davies et al.
The Journal of biological chemistry, 276(19), 16015-16023 (2001-03-30)
Synthetic high affinity peroxisome proliferator-activated receptor (PPAR) agonists are known, but biologic ligands are of low affinity. Oxidized low density lipoprotein (oxLDL) is inflammatory and signals through PPARs. We showed, by phospholipase A(1) digestion, that PPARgamma agonists in oxLDL arise
P Tontonoz et al.
Cell, 93(2), 241-252 (1998-05-06)
The formation of foam cells from macrophages in the arterial wall is characterized by dramatic changes in lipid metabolism, including increased expression of scavenger receptors and the uptake of oxidized low-density lipoprotein (oxLDL). We demonstrate here that the nuclear receptor
Douglas S Watson et al.
Vaccine, 27(34), 4672-4683 (2009-06-13)
The membrane proximal region (MPR) of HIV-1 gp41 is a desirable target for development of a vaccine that elicits neutralizing antibodies since the patient-derived monoclonal antibodies, 2F5 and 4E10, bind to the MPR and neutralize primary HIV isolates. The 2F5
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持